Adebowale Adeniran, MD
Biography
Adebowale Adeniran, MD, is a pathologist who specializes in diagnosing diseases of the genitourinary system (reproductive and urinary organs). He identifies kidney, prostate, and bladder cancers from patients’ biopsies. Dr. Adeniran also specializes in diagnosing thyroid diseases and cancer.
“The principal role of the pathologist is to provide an accurate diagnosis of a patient’s condition, which allows the physician to refine treatment options,” he says. “Pathologists and physicians work together to toward providing the best patient care.”
Dr. Adeniran decided to pursue pathology as a specialty during an academic fellowship at the University of Cincinnati Medical Center. “I saw the impact pathologists could have in terms treatment for patients by the diagnoses they made,” he says.
As director of the cytopathology and cytology labs at Yale School of Medicine, Dr. Adeniran oversees those daily operations and provides guidance to medical students and residents who are completing their training after medical school.
At the medical school, Dr. Adeniran is associate professor of pathology. In his research, he investigates the basic biology behind a cancer called papillary renal cell carcinoma and also works to better understand the molecular underpinnings of thyroid cancer.
Titles
- Professor of Pathology
- Director of Cytopathology
- Director, Cytology Laboratory
- Director, Cytopathology Fellowship Program, Pathology
- Director, Anatomic Pathology Elective Program, Pathology
Education & Training
- FellowMemorial Sloan Kettering Cancer Center (2008)
- FellowM.D. Anderson Cancer Center (2007)
- ResidentUniversity of Cincinnati Medical Center (2006)
- MDUniversity of Ibadan (1995)
Languages Spoken
- English
- Ελληνικά (Greek)
- Yorùbá (Yoruba)
Additional Information
- The Averill A. Liebow Award for Excellence in the Teaching of Pathology Residents: Department of Pathology, Yale School of Medicine (2022)
- Urology Residents Teacher of the year Award: Department of Urology, Yale School of Medicine (2014)
- The Averill A. Liebow Award for Excellence in the Teaching of Pathology Resident: Department of Pathology, Yale University School of Medicine (2011)
- 2007 Benjamin Castleman Award for the best published paper in the field of human pathology: United States and Canadian Academy of Pathology (USCAP) (2007)
- 2005 Resident Education Scholarship: The Group for Research in Pathology Education (GRIPE) (2005)
- AB of Pathology, Cytopathology (2008, recertified: 2019)
- AB of Pathology, Anatomic & Clinical Pathology (2007, recertified: 2018)
- International Accreditation Committee, College of American Pathologists (2022 - Present): Committee Member
- Education Committee, United States and Canadian Academy of Pathology (2021 - Present): Committee Member
- Clinical Practice Committee, American Society of Cytopathology (2020 - Present): Committee Member
- Tissue Committee, Yale New Haven Hospital (2018 - Present): Co-Chair
- CheckPath Clinical Pathology Committee, American Society for Clinical Pathology (2018 - Present): Committee Member
- Savion-Gaiger N, Perales O, Su D, Bar-Ziv D, Challa P, Djureinovic D, Yi I, Adeniran A, Kluger H, Schoenfeld D. Compartment-specific immune and tumor markers associated with clinical outcomes in patients with and without sarcomatoid/rhabdoid renal cell carcinoma treated with ipilimumab and nivolumab. ESMO Open 2026, 11: 106908. PMID: 42013628, PMCID: PMC13123346, DOI: 10.1016/j.esmoop.2026.106908.
- Ordobazari A, Nikfar R, Zhao X, Davaro E, Niyazi S, Rogers J, Dhillon J, Cao B, Li R, Spiess P, Pow‐Sang J, Adeniran A, Jorda M, Vosoughi A. Evaluating the Performance of the Paris System in Neobladder Cytology: The Role of Cellularity and Volume Adequacy Criteria. Diagnostic Cytopathology 2026, 54: 299-306. PMID: 41567090, DOI: 10.1002/dc.70087.
- Wang M, Abi‐Raad R, Adeniran A, Krishnamurti U, Buza N, Hui P, Cai G, Sun T. Prognostic significance of pelvic washing cytology in early stage endometrial cancer: A 10‐year matched cohort analysis from a large single institute. Cancer Cytopathology 2025, 133: e70057. PMID: 41159755, DOI: 10.1002/cncy.70057.
- Yu S, Wang M, Langdon J, Zhao J, Pai S, Sinard J, Cai G, Prasad M, Adeniran A. American College of Radiology–Developed Thyroid Imaging Reporting and Data System 3, 4, and 5 thyroid nodules are distinctive by cytology, genetic imprints, and histology. Cancer Cytopathology 2025, 133: e70050. PMID: 41021263, DOI: 10.1002/cncy.70050.
- Yi I, Ofir Y, Mann J, Su D, Kim T, Perales O, Zhang L, Adeniran A, Kluger H, Schoenfeld D. PRAME is not a frequently expressed antigen in renal cell carcinoma. BJUI Compass 2025, 6: e70037. PMID: 40453487, PMCID: PMC12123051, DOI: 10.1002/bco2.70037.
- Takeda K, Tang H, Kumar D, Adeniran A, Cai G. Clinicopathologic characteristics of lymphoproliferative disorders involving the kidney. American Journal Of Clinical Pathology 2025, 164: 192-199. PMID: 40418705, DOI: 10.1093/ajcp/aqaf023.
- Tang H, Xia H, Sun N, Hernandez P, Wang M, Adeniran A, Cai G. Selection of neuroendocrine markers in diagnostic workup of neuroendocrine neoplasms: The real‐world data and machine learning model algorithms. Cancer Cytopathology 2025, 133: e70018. PMID: 40289395, DOI: 10.1002/cncy.70018.
- Weiss S, Djureinovic D, Wei W, Tran T, Austin M, Markowitz J, Eroglu Z, Khushalani N, Hegde U, Cohen J, Sznol M, Anderson G, Johnson B, Piteo C, Mahajan A, Adeniran A, Jilaveanu L, Goldberg S, Chiang V, Forsyth P, Kluger H. Phase II Trial of Pembrolizumab in Combination With Bevacizumab for Untreated Melanoma Brain Metastases. Journal Of Clinical Oncology 2025, 43: 1685-1694. PMID: 40048689, PMCID: PMC12058415, DOI: 10.1200/jco-24-02219.
- Barata P, Tangen C, Plets M, Thompson I, Narayan V, George D, Heng D, Shuch B, Stein M, Gulati S, Tretiakova M, Tripathi A, Bjarnason G, Humphrey P, Adeniran A, Vaishampayan U, Alva A, Zhang T, Cole S, Lara P, Lerner S, Balzer-Haas N, Pal S. Final Overall Survival Analysis of S1500: A Randomized, Phase II Study Comparing Sunitinib With Cabozantinib, Crizotinib, and Savolitinib in Advanced Papillary Renal Cell Carcinoma. Journal Of Clinical Oncology 2024, 42: 3911-3916. PMID: 39255440, PMCID: PMC11575905, DOI: 10.1200/jco.24.00767.
- Rahman S, Kong V, Jalfon M, Hesse D, Kim J, Wright J, Adeniran A, Humphrey P, Martin D, Ghali F. Evaluating Treatment Patterns and the Role of Neoadjuvant Chemotherapy in Plasmacytoid Urothelial Carcinoma: Insights from a Combined National and Institutional Series. Cancers 2024, 16: 3050. PMID: 39272908, PMCID: PMC11394101, DOI: 10.3390/cancers16173050.
- Perales O, Jilaveanu L, Adeniran A, Su D, Hurwitz M, Braun D, Kluger H, Schoenfeld D. TIGIT expression in renal cell carcinoma infiltrating T cells is variable and inversely correlated with PD-1 and LAG3. Cancer Immunology, Immunotherapy 2024, 73: 192. PMID: 39105820, PMCID: PMC11303630, DOI: 10.1007/s00262-024-03773-8.
- Mann J, Hasson N, Su D, Adeniran A, Smalley K, Djureinovic D, Jilaveanu L, Schoenfeld D, Kluger H. GP100 expression is variable in intensity in melanoma. Cancer Immunology, Immunotherapy 2024, 73: 191. PMID: 39105816, PMCID: PMC11303354, DOI: 10.1007/s00262-024-03776-5.
- Tripathi A, Tangen C, Plets M, Li X, Tretiakova M, Humphrey P, Adeniran A, Barata P, Gulati S, Bergerot C, Pruthi D, Thompson I, Lara P, Lerner S, Pal S, Shuch B. Pathological concordance rate and outcomes by subtype in advanced papillary renal cell carcinoma. BJU International 2024, 134: 596-601. PMID: 39014969, DOI: 10.1111/bju.16403.
- Takeda K, Adeniran A, Levi A, Tang H, Cai G. Cytomorphological characteristics of low‐grade papillary urothelial carcinoma in voided urine samples: Distinction from benign and high‐grade papillary urothelial carcinoma. Cytopathology 2024, 35: 724-732. PMID: 38992916, DOI: 10.1111/cyt.13413.
- Takeda K, Cai G, Adeniran A, Sun T. Reevaluation of ovarian cyst fine-needle aspiration cytology: A 10-year institutional experience. American Journal Of Clinical Pathology 2024, 162: aqae077. PMID: 38916141, DOI: 10.1093/ajcp/aqae077.
- Adeniran A, Shuch B, Humphrey P. Sarcomatoid and Rhabdoid Renal Cell Carcinoma. The American Journal Of Surgical Pathology 2024, 48: e65-e88. PMID: 38736105, DOI: 10.1097/pas.0000000000002233.
- Khajir G, Sun T, Wang H, Sprenkle P, Adeniran A, Cai G, Levi A. Cytologic evaluation of upper urinary tract specimens: An institutional retrospective study using The Paris System for Reporting Urine Cytology second edition with histopathologic follow‐up. Cytopathology 2023, 35: 235-241. PMID: 37916579, DOI: 10.1111/cyt.13328.
- Schoenfeld D, Moutafi M, Martinez S, Djureinovic D, Merkin R, Adeniran A, Braun D, Signoretti S, Choueiri T, Parisi F, Hurwitz M, Rimm D, Wei W, Jilaveanu L, Kluger H. Immune dysfunction revealed by digital spatial profiling of immuno-oncology markers in progressive stages of renal cell carcinoma and in brain metastases. Journal For ImmunoTherapy Of Cancer 2023, 11: e007240. PMID: 37586773, PMCID: PMC10432651, DOI: 10.1136/jitc-2023-007240.
- Sardana R, Abi‐Raad R, Adeniran A, Cai G. Utility of parathyroid hormone immunocytochemistry in fine needle aspiration diagnosis of parathyroid tissue. Cytopathology 2023, 34: 597-602. PMID: 37534757, DOI: 10.1111/cyt.13283.
- Caulfield J, Aizenbud L, Perdigoto A, Meffre E, Jilaveanu L, Michalek D, Rich S, Aizenbud Y, Adeniran A, Herold K, Austin M, Kluger H. Germline genetic variants are associated with development of insulin-dependent diabetes in cancer patients treated with immune checkpoint inhibitors. Journal For ImmunoTherapy Of Cancer 2023, 11: e006570. PMID: 36898736, PMCID: PMC10008335, DOI: 10.1136/jitc-2022-006570.
- Meiklejohn K, Hrones M, Wang M, Prasad M, Cai G, Adeniran A, Gilani S. Diagnosis of acinic cell carcinoma of the salivary gland on cytology specimens: Role of NOR‐1 (NR4A3) immunohistochemistry. Cytopathology 2023, 34: 219-224. PMID: 36825365, DOI: 10.1111/cyt.13222.
- Schoenfeld D, Merkin R, Moutafi M, Martinez S, Adeniran A, Kumar D, Jilaveanu L, Hurwitz M, Rimm D, Kluger H. Location matters: LAG3 levels are lower in renal cell carcinoma metastatic sites compared to primary tumors, and expression at metastatic sites only may have prognostic importance. Frontiers In Oncology 2022, 12: 990367. PMID: 36313654, PMCID: PMC9608089, DOI: 10.3389/fonc.2022.990367.
- Cai G, Adeniran A. Overview. 2019, 3-11. DOI: 10.1007/978-3-030-21799-0_1.
- Adeniran A. Salivary Gland. 2019, 93-118. DOI: 10.1007/978-3-030-21799-0_5.
- Adeniran A. Telecytopathology. 2019, 413-420. DOI: 10.1007/978-3-030-21799-0_16.
- Adeniran A. Kidney and Adrenal Gland. 2019, 187-223. DOI: 10.1007/978-3-030-21799-0_8.
- Adeniran A. Thyroid. 2019, 31-60. DOI: 10.1007/978-3-030-21799-0_3.
- van Riet PA, Cahen DL, Biermann K, Hansen B, Larghi A, Rindi G, Fellegara G, Arcidiacono P, Doglioni C, Decarli N, Iglesias‐Garcia J, Abdulkader I, Iglesias H, Kitano M, Chikugo T, Yasukawa S, van der Valk H, Nguyen N, Ruszkiewicz A, Giovannini M, Poizat F, van der Merwe S, Roskams T, Santo E, Marmor S, Chang K, Lin F, Farrell J, Robert M, Bucobo J, Heimann A, Baldaque‐Silva F, Moro C, Bruno M, Attili F, Aslanian H, Adeniran A, Lee J, Petrone M, Bories E, Scapa E, Buscaglia J, Wu M. Agreement on endoscopic ultrasonography‐guided tissue specimens: Comparing a 20‐G fine‐needle biopsy to a 25‐G fine‐needle aspiration needle among academic and non‐academic pathologists. Digestive Endoscopy 2019, 31: 690-697. PMID: 31290176, PMCID: PMC6900144, DOI: 10.1111/den.13424.
- Peterss S, Mansour AM, Ross JA, Vaitkeviciute I, Charilaou P, Dumfarth J, Fang H, Ziganshin BA, Rizzo JA, Adeniran AJ, Elefteriades JA. Changing Pathology of the Thoracic Aorta From Acute to Chronic Dissection Literature Review and Insights. Journal Of The American College Of Cardiology 2016, 68: 1054-1065. PMID: 27585511, DOI: 10.1016/j.jacc.2016.05.091.
- Mafolasire A, Yao X, Nawaf C, Suarez‐Sarmiento A, Chow W, Zhao W, Corley D, Hofmann JN, Purdue M, Adeniran AJ, Shuch B. Racial disparities in renal cell carcinoma: a single‐payer healthcare experience. Cancer Medicine 2016, 5: 2101-2108. PMID: 27228559, PMCID: PMC4884637, DOI: 10.1002/cam4.755.
- Bi M, Zhao S, Said JW, Merino MJ, Adeniran AJ, Xie Z, Nawaf CB, Choi J, Belldegrun AS, Pantuck AJ, Kluger HM, Bilgüvar K, Lifton RP, Shuch B. Genomic characterization of sarcomatoid transformation in clear cell renal cell carcinoma. Proceedings Of The National Academy Of Sciences Of The United States Of America 2016, 113: 2170-2175. PMID: 26864202, PMCID: PMC4776463, DOI: 10.1073/pnas.1525735113.
- Adeniran A, Chhieng D. Common Diagnostic Pitfalls in Thyroid Cytopathology. 2016 DOI: 10.1007/978-3-319-31602-4.
- Adeniran A. Thyroid and Parathyroid Tumors. 2015, 341-374. DOI: 10.1007/978-3-319-16304-8_11.
- Shen S, Adeniran A, Tamboli P. 13 Nonepithelial Neoplasms of the Kidney. 2013, 269-290. DOI: 10.1016/b978-0-443-06966-6.00015-5.
- Feifer A, Savage C, Rayala H, Lowrance W, Gotto G, Sprenkle P, Gupta A, Taylor J, Bernstein M, Adeniran A, Tickoo SK, Reuter VE, Russo P. Prognostic Impact of Muscular Venous Branch Invasion in Localized Renal Cell Carcinoma Cases. Journal Of Urology 2010, 185: 37-42. PMID: 21074196, PMCID: PMC3437930, DOI: 10.1016/j.juro.2010.08.084.
Biography
Adebowale Adeniran, MD, is a pathologist who specializes in diagnosing diseases of the genitourinary system (reproductive and urinary organs). He identifies kidney, prostate, and bladder cancers from patients’ biopsies. Dr. Adeniran also specializes in diagnosing thyroid diseases and cancer.
“The principal role of the pathologist is to provide an accurate diagnosis of a patient’s condition, which allows the physician to refine treatment options,” he says. “Pathologists and physicians work together to toward providing the best patient care.”
Dr. Adeniran decided to pursue pathology as a specialty during an academic fellowship at the University of Cincinnati Medical Center. “I saw the impact pathologists could have in terms treatment for patients by the diagnoses they made,” he says.
As director of the cytopathology and cytology labs at Yale School of Medicine, Dr. Adeniran oversees those daily operations and provides guidance to medical students and residents who are completing their training after medical school.
At the medical school, Dr. Adeniran is associate professor of pathology. In his research, he investigates the basic biology behind a cancer called papillary renal cell carcinoma and also works to better understand the molecular underpinnings of thyroid cancer.
Titles
- Professor of Pathology
- Director of Cytopathology
- Director, Cytology Laboratory
- Director, Cytopathology Fellowship Program, Pathology
- Director, Anatomic Pathology Elective Program, Pathology
Education & Training
- FellowMemorial Sloan Kettering Cancer Center (2008)
- FellowM.D. Anderson Cancer Center (2007)
- ResidentUniversity of Cincinnati Medical Center (2006)
- MDUniversity of Ibadan (1995)
Languages Spoken
- English
- Ελληνικά (Greek)
- Yorùbá (Yoruba)
Additional Information
- The Averill A. Liebow Award for Excellence in the Teaching of Pathology Residents: Department of Pathology, Yale School of Medicine (2022)
- Urology Residents Teacher of the year Award: Department of Urology, Yale School of Medicine (2014)
- The Averill A. Liebow Award for Excellence in the Teaching of Pathology Resident: Department of Pathology, Yale University School of Medicine (2011)
- 2007 Benjamin Castleman Award for the best published paper in the field of human pathology: United States and Canadian Academy of Pathology (USCAP) (2007)
- 2005 Resident Education Scholarship: The Group for Research in Pathology Education (GRIPE) (2005)
- AB of Pathology, Cytopathology (2008, recertified: 2019)
- AB of Pathology, Anatomic & Clinical Pathology (2007, recertified: 2018)
- International Accreditation Committee, College of American Pathologists (2022 - Present): Committee Member
- Education Committee, United States and Canadian Academy of Pathology (2021 - Present): Committee Member
- Clinical Practice Committee, American Society of Cytopathology (2020 - Present): Committee Member
- Tissue Committee, Yale New Haven Hospital (2018 - Present): Co-Chair
- CheckPath Clinical Pathology Committee, American Society for Clinical Pathology (2018 - Present): Committee Member
- Savion-Gaiger N, Perales O, Su D, Bar-Ziv D, Challa P, Djureinovic D, Yi I, Adeniran A, Kluger H, Schoenfeld D. Compartment-specific immune and tumor markers associated with clinical outcomes in patients with and without sarcomatoid/rhabdoid renal cell carcinoma treated with ipilimumab and nivolumab. ESMO Open 2026, 11: 106908. PMID: 42013628, PMCID: PMC13123346, DOI: 10.1016/j.esmoop.2026.106908.
- Ordobazari A, Nikfar R, Zhao X, Davaro E, Niyazi S, Rogers J, Dhillon J, Cao B, Li R, Spiess P, Pow‐Sang J, Adeniran A, Jorda M, Vosoughi A. Evaluating the Performance of the Paris System in Neobladder Cytology: The Role of Cellularity and Volume Adequacy Criteria. Diagnostic Cytopathology 2026, 54: 299-306. PMID: 41567090, DOI: 10.1002/dc.70087.
- Wang M, Abi‐Raad R, Adeniran A, Krishnamurti U, Buza N, Hui P, Cai G, Sun T. Prognostic significance of pelvic washing cytology in early stage endometrial cancer: A 10‐year matched cohort analysis from a large single institute. Cancer Cytopathology 2025, 133: e70057. PMID: 41159755, DOI: 10.1002/cncy.70057.
- Yu S, Wang M, Langdon J, Zhao J, Pai S, Sinard J, Cai G, Prasad M, Adeniran A. American College of Radiology–Developed Thyroid Imaging Reporting and Data System 3, 4, and 5 thyroid nodules are distinctive by cytology, genetic imprints, and histology. Cancer Cytopathology 2025, 133: e70050. PMID: 41021263, DOI: 10.1002/cncy.70050.
- Yi I, Ofir Y, Mann J, Su D, Kim T, Perales O, Zhang L, Adeniran A, Kluger H, Schoenfeld D. PRAME is not a frequently expressed antigen in renal cell carcinoma. BJUI Compass 2025, 6: e70037. PMID: 40453487, PMCID: PMC12123051, DOI: 10.1002/bco2.70037.
- Takeda K, Tang H, Kumar D, Adeniran A, Cai G. Clinicopathologic characteristics of lymphoproliferative disorders involving the kidney. American Journal Of Clinical Pathology 2025, 164: 192-199. PMID: 40418705, DOI: 10.1093/ajcp/aqaf023.
- Tang H, Xia H, Sun N, Hernandez P, Wang M, Adeniran A, Cai G. Selection of neuroendocrine markers in diagnostic workup of neuroendocrine neoplasms: The real‐world data and machine learning model algorithms. Cancer Cytopathology 2025, 133: e70018. PMID: 40289395, DOI: 10.1002/cncy.70018.
- Weiss S, Djureinovic D, Wei W, Tran T, Austin M, Markowitz J, Eroglu Z, Khushalani N, Hegde U, Cohen J, Sznol M, Anderson G, Johnson B, Piteo C, Mahajan A, Adeniran A, Jilaveanu L, Goldberg S, Chiang V, Forsyth P, Kluger H. Phase II Trial of Pembrolizumab in Combination With Bevacizumab for Untreated Melanoma Brain Metastases. Journal Of Clinical Oncology 2025, 43: 1685-1694. PMID: 40048689, PMCID: PMC12058415, DOI: 10.1200/jco-24-02219.
- Barata P, Tangen C, Plets M, Thompson I, Narayan V, George D, Heng D, Shuch B, Stein M, Gulati S, Tretiakova M, Tripathi A, Bjarnason G, Humphrey P, Adeniran A, Vaishampayan U, Alva A, Zhang T, Cole S, Lara P, Lerner S, Balzer-Haas N, Pal S. Final Overall Survival Analysis of S1500: A Randomized, Phase II Study Comparing Sunitinib With Cabozantinib, Crizotinib, and Savolitinib in Advanced Papillary Renal Cell Carcinoma. Journal Of Clinical Oncology 2024, 42: 3911-3916. PMID: 39255440, PMCID: PMC11575905, DOI: 10.1200/jco.24.00767.
- Rahman S, Kong V, Jalfon M, Hesse D, Kim J, Wright J, Adeniran A, Humphrey P, Martin D, Ghali F. Evaluating Treatment Patterns and the Role of Neoadjuvant Chemotherapy in Plasmacytoid Urothelial Carcinoma: Insights from a Combined National and Institutional Series. Cancers 2024, 16: 3050. PMID: 39272908, PMCID: PMC11394101, DOI: 10.3390/cancers16173050.
- Perales O, Jilaveanu L, Adeniran A, Su D, Hurwitz M, Braun D, Kluger H, Schoenfeld D. TIGIT expression in renal cell carcinoma infiltrating T cells is variable and inversely correlated with PD-1 and LAG3. Cancer Immunology, Immunotherapy 2024, 73: 192. PMID: 39105820, PMCID: PMC11303630, DOI: 10.1007/s00262-024-03773-8.
- Mann J, Hasson N, Su D, Adeniran A, Smalley K, Djureinovic D, Jilaveanu L, Schoenfeld D, Kluger H. GP100 expression is variable in intensity in melanoma. Cancer Immunology, Immunotherapy 2024, 73: 191. PMID: 39105816, PMCID: PMC11303354, DOI: 10.1007/s00262-024-03776-5.
- Tripathi A, Tangen C, Plets M, Li X, Tretiakova M, Humphrey P, Adeniran A, Barata P, Gulati S, Bergerot C, Pruthi D, Thompson I, Lara P, Lerner S, Pal S, Shuch B. Pathological concordance rate and outcomes by subtype in advanced papillary renal cell carcinoma. BJU International 2024, 134: 596-601. PMID: 39014969, DOI: 10.1111/bju.16403.
- Takeda K, Adeniran A, Levi A, Tang H, Cai G. Cytomorphological characteristics of low‐grade papillary urothelial carcinoma in voided urine samples: Distinction from benign and high‐grade papillary urothelial carcinoma. Cytopathology 2024, 35: 724-732. PMID: 38992916, DOI: 10.1111/cyt.13413.
- Takeda K, Cai G, Adeniran A, Sun T. Reevaluation of ovarian cyst fine-needle aspiration cytology: A 10-year institutional experience. American Journal Of Clinical Pathology 2024, 162: aqae077. PMID: 38916141, DOI: 10.1093/ajcp/aqae077.
- Adeniran A, Shuch B, Humphrey P. Sarcomatoid and Rhabdoid Renal Cell Carcinoma. The American Journal Of Surgical Pathology 2024, 48: e65-e88. PMID: 38736105, DOI: 10.1097/pas.0000000000002233.
- Khajir G, Sun T, Wang H, Sprenkle P, Adeniran A, Cai G, Levi A. Cytologic evaluation of upper urinary tract specimens: An institutional retrospective study using The Paris System for Reporting Urine Cytology second edition with histopathologic follow‐up. Cytopathology 2023, 35: 235-241. PMID: 37916579, DOI: 10.1111/cyt.13328.
- Schoenfeld D, Moutafi M, Martinez S, Djureinovic D, Merkin R, Adeniran A, Braun D, Signoretti S, Choueiri T, Parisi F, Hurwitz M, Rimm D, Wei W, Jilaveanu L, Kluger H. Immune dysfunction revealed by digital spatial profiling of immuno-oncology markers in progressive stages of renal cell carcinoma and in brain metastases. Journal For ImmunoTherapy Of Cancer 2023, 11: e007240. PMID: 37586773, PMCID: PMC10432651, DOI: 10.1136/jitc-2023-007240.
- Sardana R, Abi‐Raad R, Adeniran A, Cai G. Utility of parathyroid hormone immunocytochemistry in fine needle aspiration diagnosis of parathyroid tissue. Cytopathology 2023, 34: 597-602. PMID: 37534757, DOI: 10.1111/cyt.13283.
- Caulfield J, Aizenbud L, Perdigoto A, Meffre E, Jilaveanu L, Michalek D, Rich S, Aizenbud Y, Adeniran A, Herold K, Austin M, Kluger H. Germline genetic variants are associated with development of insulin-dependent diabetes in cancer patients treated with immune checkpoint inhibitors. Journal For ImmunoTherapy Of Cancer 2023, 11: e006570. PMID: 36898736, PMCID: PMC10008335, DOI: 10.1136/jitc-2022-006570.
- Meiklejohn K, Hrones M, Wang M, Prasad M, Cai G, Adeniran A, Gilani S. Diagnosis of acinic cell carcinoma of the salivary gland on cytology specimens: Role of NOR‐1 (NR4A3) immunohistochemistry. Cytopathology 2023, 34: 219-224. PMID: 36825365, DOI: 10.1111/cyt.13222.
- Schoenfeld D, Merkin R, Moutafi M, Martinez S, Adeniran A, Kumar D, Jilaveanu L, Hurwitz M, Rimm D, Kluger H. Location matters: LAG3 levels are lower in renal cell carcinoma metastatic sites compared to primary tumors, and expression at metastatic sites only may have prognostic importance. Frontiers In Oncology 2022, 12: 990367. PMID: 36313654, PMCID: PMC9608089, DOI: 10.3389/fonc.2022.990367.
- Cai G, Adeniran A. Overview. 2019, 3-11. DOI: 10.1007/978-3-030-21799-0_1.
- Adeniran A. Salivary Gland. 2019, 93-118. DOI: 10.1007/978-3-030-21799-0_5.
- Adeniran A. Telecytopathology. 2019, 413-420. DOI: 10.1007/978-3-030-21799-0_16.
- Adeniran A. Kidney and Adrenal Gland. 2019, 187-223. DOI: 10.1007/978-3-030-21799-0_8.
- Adeniran A. Thyroid. 2019, 31-60. DOI: 10.1007/978-3-030-21799-0_3.
- van Riet PA, Cahen DL, Biermann K, Hansen B, Larghi A, Rindi G, Fellegara G, Arcidiacono P, Doglioni C, Decarli N, Iglesias‐Garcia J, Abdulkader I, Iglesias H, Kitano M, Chikugo T, Yasukawa S, van der Valk H, Nguyen N, Ruszkiewicz A, Giovannini M, Poizat F, van der Merwe S, Roskams T, Santo E, Marmor S, Chang K, Lin F, Farrell J, Robert M, Bucobo J, Heimann A, Baldaque‐Silva F, Moro C, Bruno M, Attili F, Aslanian H, Adeniran A, Lee J, Petrone M, Bories E, Scapa E, Buscaglia J, Wu M. Agreement on endoscopic ultrasonography‐guided tissue specimens: Comparing a 20‐G fine‐needle biopsy to a 25‐G fine‐needle aspiration needle among academic and non‐academic pathologists. Digestive Endoscopy 2019, 31: 690-697. PMID: 31290176, PMCID: PMC6900144, DOI: 10.1111/den.13424.
- Peterss S, Mansour AM, Ross JA, Vaitkeviciute I, Charilaou P, Dumfarth J, Fang H, Ziganshin BA, Rizzo JA, Adeniran AJ, Elefteriades JA. Changing Pathology of the Thoracic Aorta From Acute to Chronic Dissection Literature Review and Insights. Journal Of The American College Of Cardiology 2016, 68: 1054-1065. PMID: 27585511, DOI: 10.1016/j.jacc.2016.05.091.
- Mafolasire A, Yao X, Nawaf C, Suarez‐Sarmiento A, Chow W, Zhao W, Corley D, Hofmann JN, Purdue M, Adeniran AJ, Shuch B. Racial disparities in renal cell carcinoma: a single‐payer healthcare experience. Cancer Medicine 2016, 5: 2101-2108. PMID: 27228559, PMCID: PMC4884637, DOI: 10.1002/cam4.755.
- Bi M, Zhao S, Said JW, Merino MJ, Adeniran AJ, Xie Z, Nawaf CB, Choi J, Belldegrun AS, Pantuck AJ, Kluger HM, Bilgüvar K, Lifton RP, Shuch B. Genomic characterization of sarcomatoid transformation in clear cell renal cell carcinoma. Proceedings Of The National Academy Of Sciences Of The United States Of America 2016, 113: 2170-2175. PMID: 26864202, PMCID: PMC4776463, DOI: 10.1073/pnas.1525735113.
- Adeniran A, Chhieng D. Common Diagnostic Pitfalls in Thyroid Cytopathology. 2016 DOI: 10.1007/978-3-319-31602-4.
- Adeniran A. Thyroid and Parathyroid Tumors. 2015, 341-374. DOI: 10.1007/978-3-319-16304-8_11.
- Shen S, Adeniran A, Tamboli P. 13 Nonepithelial Neoplasms of the Kidney. 2013, 269-290. DOI: 10.1016/b978-0-443-06966-6.00015-5.
- Feifer A, Savage C, Rayala H, Lowrance W, Gotto G, Sprenkle P, Gupta A, Taylor J, Bernstein M, Adeniran A, Tickoo SK, Reuter VE, Russo P. Prognostic Impact of Muscular Venous Branch Invasion in Localized Renal Cell Carcinoma Cases. Journal Of Urology 2010, 185: 37-42. PMID: 21074196, PMCID: PMC3437930, DOI: 10.1016/j.juro.2010.08.084.